首页> 美国卫生研究院文献>Quantitative Imaging in Medicine and Surgery >The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications
【2h】

The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications

机译:第八届肺癌TNM分类和临床分期系统:回顾其变化及其临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment.
机译:肺癌是男女死亡的主要原因。临床分期在预测肺癌患者的幸存者以及影响治疗选择方面起着至关重要的作用。随着越来越多的数据可用于提供最准确的预后指标,指南不断地被审查,从而有助于肺癌的临床检测和分期。自1970年代引入以来,TNM分期已进行了重大修订,最新的第8版,从2018年开始在国际上生效。该版本重新分类了肿瘤大小和其他非量化的肿瘤描述符(T),并进一步细分胸外转移(M)。临床节点(N)分类器没有变化,因为早期版本与预后良好相关。强调了在过渡上的下游影响以适应新的T和M分类。存活率与肿瘤大小每增加1厘米成反比,直到7厘米,达到与T4疾病相同的预后。因此,一些基于肿瘤大小的T-分类器被升级以反映这一点。隔膜的浸润被认为是T4而不是T3。另一方面,不管肿瘤与隆突之间的距离以及肺不张,不管是从T3疾病到T2疾病,主支气管的受累程度都降低了。自第7版以来,已经引入了称为原位腺癌(AIS)和微创腺癌(MIA)的新型肺肿瘤。本手稿中还介绍了T定义功能。在第7版中被分类为M1b的胸外转移灶在第8版中被进一步分为M1b和M1c,以更好地定义具有较好预后的少发转移,并且可能会从更积极的局部治疗中受益。本概述旨在为放射科医生提供最新版本变化的描述,包括亚固体和多个结节的分期,概述第8版的潜在局限性以及对治疗的影响的讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号